Discovery and Chemical Affinity
In 1935, the German researcher G. Domagk identified a pronounced antimicrobial effect in a drug called Prontosil (also known as red streptocide). It was subsequently discovered that Prontosil itself is merely a prodrug. Upon entering the human body, it undergoes metabolic transformations that release the truly active therapeutic agent—sulfanilamide (white streptocide). This discovery marked the beginning of a whole class of medications.
The main secret to the efficacy of these drugs lies in their molecular structure. Sulfonamides are structural analogs of para-aminobenzoic acid (PABA). PABA itself is a vital component for microorganisms because it is incorporated into the folic acid molecule. Folic acid is constructed from three fundamental building blocks: pterin, PABA, and glutamic acid. Sulfonamides share a common core formula containing a sulfonamide group, where various radicals determine the properties of a specific drug (for example, streptocide has a hydrogen atom, albucid [sulfacetamide] has an acetyl group, and sulfadimidine has a heterocycle with methyl groups).
Molecular Mechanisms of the Bacteriostatic Effect
Based on their pharmacological action, sulfonamides are bacteriostatic. They do not kill bacteria outright; rather, they reliably halt further microbial growth and reproduction.
This effect is based on the phenomenon of competitive inhibition. Because a sulfonamide molecule closely resembles PABA in shape, it can displace PABA in the bacterial enzyme dihydropteroate synthase. This enzyme normally captures PABA to assemble folic acid. The presence of the drug leads to the sulfonamide taking the place of PABA in the active site of the enzyme.
The result of this substitution is the complete blockade of folic acid synthesis inside the bacterial cell. Because folates are critically required by microorganisms for the biosynthesis of nucleic acids (DNA and RNA), folic acid deficiency makes the duplication of genetic material impossible. Consequently, the bacterial cell loses its ability to divide.
Enzyme Kinetics and the Loading Dose Rule
The biochemical essence of competitive inhibition is clearly demonstrated when analyzing the kinetic constants of the enzymatic reaction:
- Maximum reaction velocity ($V_{max}$) remains unchanged. This means that if an enormous theoretical excess of PABA were present in the environment, it could displace the inhibitor, and the enzyme would operate at full capacity.
- Michaelis constant ($K_m$) significantly increases. This indicates that the affinity of dihydropteroate synthase for its true substrate (PABA) sharply decreases in the presence of the inhibitor.
It is precisely this biochemical feature that dictates the strict rules for the clinical application of these drugs. To make treatment effective, it is necessary to establish a drug concentration in the blood that vastly exceeds the concentration of PABA in the tissues. For this reason, therapy is always initiated with a so-called loading dose. This rapidly shifts the equilibrium in the competitive battle for the active site of the enzyme in favor of the drug.
Biochemical Basis of Selective Toxicity
One of the main questions when studying antibacterial agents is why they are lethal to microbes yet safe for humans. In the case of sulfonamides, the answer lies in folate metabolism.
To survive, bacteria must synthesize folic acid de novo (from scratch). Human cells, however, are incapable of synthesizing folic acid independently and acquire it exclusively in its preformed state from the diet (as a vitamin). Consequently, human cells completely lack dihydropteroate synthase—the target enzyme for sulfonamides—which ensures their selective toxicity.